medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2006, Number 4

<< Back Next >>

Rev Invest Clin 2006; 58 (4)

Neonatal hypothyroidism. Pathophysiogenic, molecular and clinical aspects

Solis JC, Valverde C

Language: Spanish
References: 119
Page: 318-334
PDF size: 386.74 Kb.


ABSTRACT

This review provides an updated summary on both the clinical and diagnostic aspects of neonatal hypothyroidism (NeH); as well as on the molecular and pathophysiologic processes known to be involved in the installment of this important hormonal deficiency. Current information regarding its etiology and pathogenesis has allowed classigying NeH in three major groups: endemic, transient, and sporadic hypothyroidism. The later corresponds to congenital hypothyroidism and encompasses a broad spectrum of hereditary disorders causing hypothyroidism in newborns and young children. These congenital disorders include hypothalamic-pituitary or thyroid dysgenesis and/or dyshormonogenesis, as well as hyporesponsiveness or resistance to either TRH, TSH or to thyroid hormones. The introduction of national screening programs for NeH have overcome the difficulties in the early diagnosis thus helping to prevent its serious and irreversible consequences on intellectual and physical development. Concomitantly, an increase in the need for complementary etiologic and molecular diagnosis has risen. The current capability to perform a fine and precise diagnose is crucial both for treatment of the affected infant and for genetic counseling of the family. Although incomplete, available epidemiological information in Mexico indicates that NeH prevalence can be as high as twice that in other developed world countries. On these bases, national public health policies and epidemiological surveyance must be strengthen not only to identify. diagnose and timely treat, but to prevent and eradicate endemic NeH.


REFERENCES

  1. Gómez VE, Bolaños F, Valverde RC. Tiroides. En: Malacara JM, García VM, Valverde RC (Eds.). Fundamentos de endocrinología. México: Salvat; 1990.

  2. Brent GA. Tissue-specific sctions of thyroid hormone: insights from animal models. Rev Endocr Metab Disord 2000; 1(1): 27-33.

  3. Anderson GW, Mariash CN, Oppenheimer JH. Molecular actions of thyroid hormone. En: Braverman LE, Utiger RD (eds.). The thyroid: a fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, p. 977-83.

  4. Feng X, Jiang Y, Meltzer P, et al. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol 2000; 14(7): 947-55.

  5. Yen PM. Cellular action of thyroid hormone. Chapter 3. The thyroid and its diseases- Book chapters. 2003 (fecha de acceso: febrero 2006). Disponible en: http://www.thyroidmanager.org/Chapter3/3d-frame.htm

  6. Bernal J, Guadaño-Ferraz A, Morte B. Perspectives in the study of thyroid hormone action on brain development and function. Thyroid 2003; 13(11): 1005-12.

  7. Chidakel A, Mentuccia D, Celi FS. Peripheral metabolism of thyroid hormone and glucose homeostasis. Thyroid 2005; 15(8): 899-903.

  8. Pop VJ, Kuijpens JL, van Baar AL, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol 1999; 50(2): 149-55.

  9. New England congenital hypothyroidism collaborative. Correlation of cognitive test scores and adequacy of treatment in adolescents with congenital hypothyroidism. J Pediatr 1994; 124(3): 383-7.

  10. Frieden E. The chemical elements of life. Sci Am 1972; 227: 52-60.

  11. Mertz W. The essential trace elements. Science 1981; 213: 1332-8.

  12. Bloomfield MM, Stephens LJ. Chemistry and the living organisms. New York: John Wiley & Sons; 1996.

  13. Gribble GW. Naturally occurring organohalogen compounds. Accts Chem Res 1998; 31: 141-52.

  14. Emsley J. Nature’s building blocks. New York: Oxford University Press; 2001.

  15. Valverde-R C, Orozco A, Becerra A, et al. Halometabolites and cellular dehalogenase systems: an evolutionary perspective. Int Rev Cytol 2004; 234: 143-99.

  16. Gribble GW. The diversity of naturally produced organohalogens. Chemosphere 2003; 52: 289-97.

  17. Burman KD, Wartofsky L. Iodine effects on the thyroid gland: biochemical and clinical aspects. Rev Endocr Metab Disord 2000; 1(1): 19-25.

  18. Larsen PR, Davies TF, Schlumberger MJ, Hay ID. Thyroid physiology and diagnostic evaluation of patients with thyroid disorder. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds.). Williams textbook of endocrinology. Philadelphia: Saunders; 2003, p. 331-73.

  19. Pintar JE. Normal development of the hypothalamic-pituitarythyroid axis. In: Braverman LE, Utiger RD (Eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, p. 7-19.

  20. Davies TF, Ando T, Lin RY, et al. Thyrotropin receptor-associated diseases: From adenomata to Graves disease. J Clin Invest 2005; 115(8): 1972-83.

  21. Missero C, Cobellis G, De Felice M, et al. Molecular events involved in differentiation of thyroid follicular cells. Mol Cell Endocrinol 1998; 140(1-2): 37-43.

  22. Moore KL. Aparato branquial, cabeza y cuello. En: Moore KL (ed.). Embriología clínica. México: Interamericana; 1989, pp. 187-227.

  23. Radetti G, Zavallone A, Gentili L, et al. Foetal and neonatal thyroid disorders. Minerva Pediatr 2002; 54(5): 383-400.

  24. Dunn JT, Dunn AD. Update on intrathyroidal iodine metabolism. Thyroid 2001; 11(5): 407-14.

  25. Kim PS, Arvan P. Endocrinopathies in the family of endoplasmic reticulum (ER) storage diseases: Disorders of protein trafficking and the role of ER molecular chaperones. Endocr Rev 1998; 19(2): 173-202.

  26. Carrasco N. Thyroid iodide transport: the Na+/I- symporter (NIS). In: Braverman LE, Utiger RD (Eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, pp. 52-61.

  27. Taurog AM. Hormone synthesis: Thyroid iodine metabolism. In: Braverman LE, Utiger RD (Eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, pp. 61-85.

  28. Dunn JT, Dunn AD. Thyroglobulin: Chemistry, biosynthesis and proteolysis. In: Braverman LE, Utiger RD (Eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, pp. 91-104.

  29. Andersson HC, Kohn LD, Bernardini I, et al. Characterization of lysosomal monoiodotyrosine transport in rat thyroid cells. Evidence for transport by system H. J Biol Chem 1990; 265(19): 10950-4.

  30. Snyder PJ. The pituitary in hypothyroidism. In: Braverman LE, Utiger RD (Eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, pp. 811-14.

  31. Silva EJ. Catecholamines and the sympathoadrenal system in hypothyroidism. In: Braverman LE, Utiger RD (Eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, pp. 820-3.

  32. Diekman T, Lansberg PJ, Kastelein JJ, et al. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Inter Med 1995; 155(14): 1490-5.

  33. Franklyn JA. Metabolic changes in hypothyroidism. In: Braverman LE, Utiger RD (Eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, pp. 833-6.

  34. Foley TP. Congenital hypothyroidism. Hypothyroidism in infants and children. In: Braverman LE, Utiger RD (Eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, pp. 977-83.

  35. Grant DB, Smith I, Fuggle PW, et al. Congenital hypothyroidism detected by neonatal screening: Relationship between biochemical severity and early clinical features. Arch Dis Child 1992; 67(1): 87-90.

  36. Unachak K, Dejkhamron P. Primary congenital hypothyroidism: Clinical characteristics and etiological study. J Med Assoc Thai 2004; 87(6): 612-7.

  37. LaFranchi S. Congenital hypothyroidism: Etiologies, diagnosis, and management. Thyroid 1999; 9(7): 735-40.

  38. Brown R, Larsen PR. Thyroid gland development and disease in infancy and childhood. Chapter 15. The thyroid and its diseases- Book chapters. 2005 (fecha de acceso: febrero 2006). Disponible en: http://www.thyroidmanager.org/Chapter15/15-frame.htm

  39. Rovet JF, Ehrlich RM. Long-term effects of L-thyroxine therapy for congenital hypothyroidism. J Pediatr 1995; 126(3): 380-6.

  40. Glorieux J, Dussault J, Van Vliet G. Intellectual development at age 12 years of children with congenital hypothyroidism diagnosed by neonatal screening. J Pediatr 1992; 121(4): 581-4.

  41. Dussault JH, Coulombe P, Laberge C, et al. Preliminary report on a mass screening program for neonatal hypothyroidism. J Pediatr 1975; 86: 670-4.

  42. Poder-Ejecutivo-Federal. Norma técnica No 321 para la prevención del retraso mental producido por hipotiroidismo congénito. México: Gobierno Constitucional de los Estados Unidos Mexicanos. México: Diario Oficial de la Federación 1988; 14: 88-90.

  43. Vela-Amieva M, Hernández-Osorio C, Gamboa-Cardiel S, et al. Hipertirotropinemia en recién nacidos Mexicanos. Salud Pública Mex 2003; 45(4): 269-75.

  44. Moreno JC, De Vijlder JJ, Vulsma T, et al. Genetic basis of hypothyroidism: recent advances, gaps and strategies for future research. Trends Endocrinol Metab 2003; 14(7): 318-26.

  45. Hetzel BS. Iodine Deficiency Disorders (IDD), and their eradication. Lancet 1983; 2: 1126-9.

  46. World Health Organization. Assessment of iodine deficiency disorders and monitoring their elimination. A guide for programme managers. Second edition, 2001; WHO/NHD/01.1.

  47. Delange FM, Hetzel B. The iodine deficiency disorders. Chapter 20. The thyroid and its diseases - Book chapters. 2005 (fecha de acceso: febrero 2006). Disponible en: http://www.thyroidmanager.org/Chapter20/20-frame.htm

  48. Kavishe FP. Iodine deficiency disorders. In: Sadler MJ, Strain JJ, Caballero B (eds.). Encyclopedia of Human Nutrition. Vol. 3. London: Academic Press; 1999, pp. 1146-53.

  49. Vitti P, Rago T, Aghini-Lombardi F, et al. Iodine deficiency disorders in Europe. Public Health Nutrition 2001; 4(2B): 529-35.

  50. World Health Organization. Iodine deficiency disorders. WHO fact sheet No 121. Geneva, Switzerland: WHO; 1996.

  51. Hetzel BS. Eliminating iodine deficiency disorders: The role of the international council in the global partnership. Bull World Health Organ 2002; 80(5): 410-12.

  52. WHO, UNICEF, ICCIDD. Progress towards elimination of iodine deficiency disorders. Geneva: World Health Organization; 1999.

  53. Vela M, Gamboa S, Loera-Luna A, et al. Neonatal screening for congenital hypothyroidism in México: experience, obstacles, and strategies. J Med Screen 1999; 6: 77-9.

  54. Vela-Amieva M, Gamboa-Cardiel S, Pérez-Andrade ME, et al. Epidemiología del hipotiroidismo congénito en México. Salud Pública Mex 2004; 46(2): 141-8.

  55. Delange FM. Endemic cretinism. In: Braverman LE, Utiger RD (Eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, pp. 743-54.

  56. Martínez-Salgado H, Castaneda-Limones R, Lechuga-Martín del Campo D, et al. Deficiencia de yodo y otros posibles bociógenos en la persistencia del bocio endémico en México. Gac Méd Méx 2002; 138(2): 149-56.

  57. Vásquez-Garibay EM, Romero-Velarde E, Nápoles-Rodriguez F, et al. Prevalencia de deficiencia de hierro y yodo, y parasitosis en niños de Arandas, Jalisco, México. Salud Pública Mex 2002; 44(3): 195-200.

  58. Klein RZ, Mitchell ML. Hypothyroidism in infants and children. In: Braverman LE, Utiger RD (Eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, pp. 973-7.

  59. Fugazzola L, Persani L, Mannavola D, et al. Recombinant human TSH testing is a valuable tool for differential diagnosis of congenital hypothyroidism during L-thyroxine replacement. Clin Endocrinol 2003; 59(2): 230-6.

  60. De Vijlder JJ, Vulsma T. Hereditary metabolic disorders causing hypothyroidism. In: Braverman LE, Utiger RD (Eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, pp. 733-42.

  61. Kopp P. Pendred’s syndrome and genetic defects in thyroid hormone synthesis. Rev Endocr Metab Disord 2000; 1: 109-21.

  62. McKusick VA. Mendelian inheritance in man. A catalog of human genes and genetic disorders. Baltimore: Johns Hopkins University Press; 1998.

  63. Vono-Toniolo J, Kopp P. Thyroglobulin gene mutations and other genetic defects associated with congenital hypothyroidism. Arq Bras Endocrinol Metab 2004; 48(1): 70-82.

  64. Vassart G. TSH receptor mutations and diseases. Chapter 16. The thyroid and its diseases - Book chapters. 2003 (fecha de acceso: febrero 2006). Disponible en: http://www.thyroidmanager.org/Chapter16/16a-frame.htm

  65. Stenson PD, Ball EV, Mort M, et al. Human gene mutation database (HGMD): 2003 update. Hum Mutat 2003; 21(6): 577-81 (véase también: http://www.hgmd.cf.ac.uk/).

  66. Macchia PE, De Felice M, Di Lauro R. Molecular genetics of congenital hypothyroidism. Curr Opin Genet Dev 1999; 9(3): 289-94.

  67. De Felice M, Ovitt C, Biffali E, et al. A mouse model for hereditary thyroid dysgenesis and cleft palate. Nat Genet 1998; 19(4): 395-8.

  68. Tell G, Pellizzari L, Esposito G, et al. Structural defects of a Pax8 mutant that give rise to congenital hypothyroidism. Biochem J 1999; 341(Pt 1): 89-93.

  69. Macchia PE. Recent advances in understanding the molecular basis of primary congenital hypothyroidism. Mol Med Today 2000; 6(1): 36-42.

  70. Gillam MP, Kopp P. Genetic regulation of thyroid development. Curr Opin Pediatr 2001; 13(4): 358-63.

  71. Kopp P. Perspective: Genetic defects in the etiology of congenital hypothyroidism. Endocrinology 2002; 143(6): 2019-24.

  72. Refetoff S. Resistance to thyroid hormone. In: Braverman LE, Utiger RD (eds.). The thyroid: A fundamental and clinical text. New York: Lippincott Williams & Wilkins; 2000, pp. 1028-43.

  73. Refetoff S. Resistance to thyroid hormone. Chapter 16d. The thyroid and its diseases - Book chapters. 2004 (fecha de acceso: febrero 2006). Disponible en: http://www.thyroidmanager.org/Chapter16/16d-frame.htm

  74. Friesema E, Grueters A, Halestrap A. et al. Mutations in a thyroid hormone transporter in patients with severe psicomotor retardation and high serum T3 levels. Thyroid 2003; 13(7): 672.

  75. Dumitrescu AM, Liao XH, Best TB, et al. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet 2004; 74(1): 168-75.

  76. Friesema ECH, Jansen J, Visser TJ. Thyroid hormone transporters. Biochem Soc Trans 2005; 33(1): 228-32.

  77. Jansen J, Friesema ECH, Milici C, Visser TJ. Thyroid hormone transporters in health and disease. Thyroid 2005; 15(8): 757-68.

  78. Weiss RE, Refetoff S. Resistance to thyroid hormone. Reviews in Endocrine and Metabolic Disorders 2000; 1(1): 97-108.

  79. Refetoff S. Defects of thyroid hormone transport in serum. Chapter 16c. The thyroid and its diseases - Book chapters. 2004 (fecha de acceso: febrero 2006). Disponible en: http://www.thyroidmanager.org/Chapter16/16c-frame.htm

  80. Yen PM. Thyrotropin receptor mutations in thyroid diseases. Rev Endocr Metab Disorde 2000; 1(1): 123-9.

  81. Davies TF, Ando T, Lin RY, Tomer Y, et al. Thyrotropin receptor-associated diseases: From adenomata to graves disease. J Clin Invest 2005; 115(8): 1972-83.

  82. Spiegel AM. Mutations in G proteins and G protein-coupled receptors in endocrine disease. J Clin Endocrinol Metab 1996; 81(7): 2434-42.

  83. Gillam MP, Kopp P. Genetic defects in thyroid hormone synthesis. Curr Opin Pediatr 2001; 13(4): 364-72.

  84. Rodriguez AM, Perron B, Lacroix L, et al. Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J Clin Endocrinol Metab 2002; 87(7): 3500-3.

  85. Yoshida A, Taniguchi S, Hisatome I, et al. Pendrin is an iodide- specific apical porter responsible for iodide efflux from thyroid cells. J Clin Endocrinol Metab 2002; 87(7): 3356-61.

  86. Franklyn J, Shephard M. Evaluation of thyroid function in health and disease. Chapter 6e. The thyroid and its diseases - Book chapters. 2000 (fecha de acceso: febrero 2006). Disponible en: http://www.thyroidmanager.org/Chapter6/6-text.htm

  87. De Vijlder JJ. Primary congenital hypothyroidism: Defects in iodine pathways. Eur J Endocrinol 2003; 149(4): 247-56.

  88. Suzuki K, Lavaroni S, Mori A, et al. Autoregulation of thyroid-specific gene transcription by thyroglobulin. Proc Natl Acad Sci 1998; 95(14): 8251-6.

  89. Suzuki K, Nakazato M, Ulianich L, et al. Thyroglobulin autoregulation of thyroid-specific gene expression and follicular function. Rev Endocr Metab Disord 2000; 1(3): 217-24.

  90. Brix K, Lemansky P, Herzog V. Evidence for extracellularly acting cathepsins mediating thyroid hormone liberation in thyroid epithelial cells. Endocrinology 1996; 137(5): 1963-74.

  91. Linke M, Jordans S, Mach L, et al. Thyroid stimulating hormone upregulates secretion of cathepsin B from thyroid epithelial cells. Biol Chem 2002; 383(5): 773-84.

  92. Friedrichs B, Tepel C, Reinheckel T, et al. Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest 2003; 111(11): 1733-45.

  93. De Deken X, Wang D, Many MC, et al. Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J Biol Chem 2000; 275(30): 23227-33.

  94. Rosenberg IN, Goswami A. Iodotyrosine deiodinase from bovine thyroid. Methods in Enzymology 1984; 107: 488-500.

  95. Solis-S JC, Villalobos P, Orozco A, Valverde-R C. Comparative kinetic characterization of rat thyroid iodotyrosine dehalogenase and iodothyronine deiodinase type 1. J Endocrinol 2004; 181(3): 385-92.

  96. Stanbury JB, Meijer JWA, Kassenaar AAH. The metabolism of iodotyrosines. II. The metabolism of mono- and diiodotyrosine in certain patients with familial goiter. J Clin Endocrinol Metab 1956; 16: 848-61.

  97. Querido A, Stanbury JB, Kassenaar AAH, et al. The metabolism of iodotyrosines. III. Di-iodotyrosine deshalogenating activity of human thyroid tissue. J Clin Endocrinol Metab 1956; 16: 1096-112.

  98. Moreno JC, Keijser R, Aarraas S, et al. Cloning and characterization of a novel thyroidal gene encoding proteins with a conserved nitroreductase domain. J Endocrinol Invest 2002; 25:23.

  99. Gnidehou S, Caillou I, Talbot M, et al. Iodotyrosine dehalogenase 1 (DEHAL1) is a transmembrane protein involved in the recycling of iodide close to the thyroglobulin iodination site. FASEB 2004; 18: 1574-6.

  100. Huang SA, Tu HM, Harney JW, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000; 343(3): 185-9.

  101. 101.Konrad D, Ellis G, Perlman K. Spontaneous regression of severe acquired infantile hypothyroidism associated with multiple liver hemangiomas. Pediatrics 2003; 112(6): 1424-6.

  102. Huang SA, Fish SA, Dorfman DM, et al. A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. J Clin Endocrinol Metab 2002; 87(10): 4457-61.

  103. Selva KA, Mandel SH, Rien L, et al. Initial treatment dose of L-thyroxine in congenital hypothyroidism. J Pediatr 2002; 141(6): 786-92.

  104. Cassio A, Cacciari E, Cicognani A, et al. Treatment for congenital hypothyroidism: Thyroxine alone or thyroxine plus triiodothyronine? Pediatrics 2003; 111(5 Pt 1): 1055-60.

  105. Rovet JF, Ehrlich RM, Sorbara DL. Neurodevelopment in infants and preschool children with congenital hypothyroidism: Etiological and treatment factors affecting outcome. J Pediatr Psychol 1992; 17(2): 187-213.

  106. 106.Gottschalk B, Richman RA, Lewandowski L. Subtle speech and motor deficits of children with congenital hypothyroid treated early. Dev Med Child Neurol 1994; 36(3): 216-20.

  107. Rovet JF. Congenital hypothyroidism: long-term outcome. Thyroid 1999; 9(7): 741-8.

  108. Rovet JF.Children with congenital hypothyroidism and their siblings: do they really differ? Pediatrics 2005; 115(1): 52-6.

  109. Hanukoglu A, Perlman K, Shamis I, et al. Relationship of etiology to treatment in congenital hypothyroidism. J Clin Endocrinol Metab 2001; 86(1): 186-91.

  110. Oerbeck B, Sundet K, Kase BF, et al. Congenital hypothyroidism: Influence of disease severity and L-thyroxine treatment on intellectual, motor, and school-associated outcomes in young adults. Pediatrics 2003; 112(4): 923-30.

  111. Alabbasy AJ, Delbridge L, Eckstein R, et al. Microfollicular thyroid adenoma and congenital goitrous hypothyroidism. Arch Dis Child 1992; 67(10): 1294-5.

  112. Aronson R, Sochett E, Pearl RH, et al. Nodular hyperplasia in treated congenital goitrous hypothyroidism. J Pediatr Endocrinol Metab 1996; 9(6): 613-6.

  113. Hindmarsh PC. Optimization of thyroxine dose in congenital hypothyroidism. Arch Dis Child 2002; 86(2): 73-5.

  114. Hopwood NJ. Treatment of the infant with congenital hypothyroidism. J Pediatr 2002; 141(6): 752-4.

  115. Heyerdahl S, Oerbeck B. Congenital hypothyroidism: Developmental outcome in relation to levothyroxine treatment variables. Thyroid 2003; 13(11): 1029-38.

  116. Osborn DA. Thyroid hormones for preventing neurodevelopmental impairment in preterm infants. Cochrane Database Syst Rev 2001; (4): CD001070.

  117. 117.Ogilvy-Stuart AL. Neonatal thyroid disorders. Arch Dis Child Fetal Neonatal Ed 2002; 87(3): F165-F171.

  118. Rapaport R, Rose SR, Freemark M. Hypothyroxinemia in the preterm infant: the benefits and risks of thyroxine treatment. J Pediatr 2001; 139(2): 182-8.

  119. Pauws E, Moreno JC, Tijssen M, et al. Serial analysis of gene expression as a tool to assess the human thyroid expression profile and to identify novel thyroidal genes. J Clin Endocrinol Metab 2000; 85: 1923-7.




2020     |     www.medigraphic.com